DerNaPol

Pre-Clinical Stage for Chronic Wounds Treatment • Chronic wounds are a major global health issue, costing billions in treatment annually (e.g., £3.2 billion in the UK 1 in 2015; $28.1 to $96.8 billion in the USA in 20142 ). These wounds cause extreme suffering with severe symptoms, often complicated by antibioticresistant infections, impenetrable biofilms and deteriorating local tissue health. • The aim is to develop a nano-formulated product with antimicrobial, biofilm-disrupting, symptom-controlling, and wound-healing properties to address chronic wounds lacking effective treatment. • Goals of Preclinical Studies: - Identify and Select Novel Repurposed Antimicrobial Agents - Optimize Combinations for tissue health and relief - Enhance Nano-Formulation to maximize therapeutic benefits